|
|
|
|
Vol. 53, Issue 6, 1089-1096, June 1998
Laboratory of Biochemistry, School of Medicine, University of
Patras, 26110 Patras, Greece
A detailed kinetic study was carried out on the inhibitory mechanisms
of two eukaryotic peptidyltransferase drugs (I), anisomycin and
sparsomycin. In an in vitro system from rabbit
reticulocytes, AcPhe-puromycin is produced in a pseudo-first-order
reaction from the preformed AcPhe-tRNA/poly(U)/80S ribosome complex
(complex C) and excess puromycin (S). This reaction is inhibited by
anisomycin and sparsomycin through different mechanisms. Anisomycin
acts as a mixed noncompetitive inhibitor. The product, AcPhe-puromycin, is derived only from C according to the puromycin reaction. On the
other hand, sparsomycin reacts with complex C in a two-step reaction,
An
initial rapid binding of the drug produces the encounter complex CI.
During this step and before conversion of CI to C*I, sparsomycin
behaves as a competitive inhibitor. The rapidly produced CI is
isomerized slowly to a conformationally altered species C*I in which I
is bound more tightly. The rate constants of this step are
k6 = 2.1 min
1 and
k7 = 0.095 min
1.
Moreover, the low value of the association rate constant
k7/Ki' (2 × 105
M
1
sec
1), provides insight into the rates of
possible conformational changes occurring during protein synthesis and
supports the proposal that sparsomycin is the first example of a
slow-binding inhibitor of eukaryotic peptidyltransferase. When complex
C is preincubated with concentrations of sparsomycin of >8
Ki and then reacts with a mixture of
puromycin and sparsomycin, the inhibition becomes linear mixed
noncompetitive and involves C*I instead of CI. During this phase,
AcPhe-puromycin is produced from a new, modified ribosomal complex with
a lower catalytic rate constant. Thus, sparsomycin also acts as a
modifier of eukaryotic peptidyltransferase activity.
This article has been cited by other articles:
![]() |
D. A. Pace and D. T. Manahan Cost of Protein Synthesis and Energy Allocation During Development of Antarctic Sea Urchin Embryos and Larvae Biol. Bull., April 1, 2007; 212(2): 115 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, M. T. H. Abreu, K. Siminovitch, G. P. Downey, and C. A. McCulloch Phosphorylation of SHP-2 Regulates Interactions between the Endoplasmic Reticulum and Focal Adhesions to Restrict Interleukin-1-induced Ca2+ Signaling J. Biol. Chem., October 13, 2006; 281(41): 31093 - 31105. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lizak, I. Czegle, M. Csala, A. Benedetti, J. Mandl, and G. Banhegyi Translocon pores in the endoplasmic reticulum are permeable to small anions Am J Physiol Cell Physiol, September 1, 2006; 291(3): 511 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Flourakis, F. Van Coppenolle, V. Lehen'kyi, B. Beck, R. Skryma, and N. Prevarskaya Passive calcium leak via translocon is a first step for iPLA2-pathway regulated store operated channels activation FASEB J, June 1, 2006; 20(8): 1215 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Toulouse, F. Au-Yeung, C. Gaspar, J. Roussel, P. Dion, and G. A. Rouleau Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts Hum. Mol. Genet., September 15, 2005; 14(18): 2649 - 2660. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Van Coppenolle, F. Vanden Abeele, C. Slomianny, M. Flourakis, J. Hesketh, E. Dewailly, and N. Prevarskaya Ribosome-translocon complex mediates calcium leakage from endoplasmic reticulum stores J. Cell Sci., August 15, 2004; 117(18): 4135 - 4142. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Roy and W. F. Wonderlin The Permeability of the Endoplasmic Reticulum Is Dynamically Coupled to Protein Synthesis J. Biol. Chem., February 7, 2003; 278(7): 4397 - 4403. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Law, A. Raney, C. Heusner, and D. R. Morris Polyamine Regulation of Ribosome Pausing at the Upstream Open Reading Frame of S-Adenosylmethionine Decarboxylase J. Biol. Chem., October 5, 2001; 276(41): 38036 - 38043. [Abstract] [Full Text] [PDF] |
||||